Friedhelm Blobel

Friedhelm Blobel, Ph.D., currently serves as board member of private Life Science companies (ImaginAb, ENTvantage, and SciClone Pharmaceuticals International Ltd). From June 2006 until its acquisition by a Chinese consortium in October 2017 he served as President, Chief Executive Officer and a Director for SciClone Pharmaceuticals, Inc. Throughout these years SciClone was a NASDAQ listed company, based in the San Francisco Bay Area with a specialty pharmaceuticals business focused in China, managing its own sales force and recent annual revenues of approximately $150 million. From July 2000 to 2006 Dr. Blobel was President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a private South San Francisco-based biopharmaceutical company. Prior to joining Gryphon Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group, including responsibilities in the areas of diabetes and in vitro diagnostics. For these companies, he lived and worked eight years in Europe and Japan before moving to the USA. Dr. Blobel holds a Ph.D. in Biochemistry and Microbiology from the University of Hohenheim, Germany.